Three-year data from the POETYK PSO long-term extension trial of Sotyktu showed consistent efficacy and safety for the treatment of adults with moderate to severe plaque psoriasis, Bristol Myers Squibb announced in a press release.
The trial’s efficacy and safety data were presented at the European Academy of Dermatology and Venereology (EADV) 2023 Congress.
“These new 3-year data demonstrate that psoriasis patients treated with Sotyktu achieve durable and clinically meaningful improvements in skin clearance for up to 3 years,” Roland Chen, MD, senior vice president and head